Hiroz, Philippe <br/><br/>
Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.  [electronic resource] 

 -  Scandinavian journal of gastroenterology  Oct 2014 
 - 1207-18 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1502-7708 
<br/><br/><label>Standard No.: </label>10.3109/00365521.2014.946082  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anti-Inflammatory Agents, Non-Steroidal--adverse effects<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Body Mass Index<br/>Certolizumab Pegol<br/>Child<br/>Child, Preschool<br/>Cohort Studies<br/>Colitis, Ulcerative--diagnosis<br/>Crohn Disease--diagnosis<br/>Delayed Diagnosis<br/>Drug Substitution--statistics & numerical data<br/>Drug Tolerance<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--therapeutic use<br/>Infant<br/>Infliximab<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--therapeutic use<br/>Risk Factors<br/>Switzerland<br/>Time Factors<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>Young Adult